Komen Foundation Announces 1998 Postdoctoral Fellows

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

DALLAS--The Susan G. Komen Breast Cancer Foundation has announced the recipients of its 1998 postdoctoral fellowship grants, which total more than $1 million. In addition to these 10 new first-year grant recipients, the Komen Foundation currently funds 21 previously awarded fellowships throughout the United States.

DALLAS--The Susan G. Komen Breast Cancer Foundation has announced the recipients of its 1998 postdoctoral fellowship grants, which total more than $1 million. In addition to these 10 new first-year grant recipients, the Komen Foundation currently funds 21 previously awarded fellowships throughout the United States.

These fellowships represent the Foundation’s continued commitment to recruiting and retaining young scientists in the field of breast cancer research and to funding innovative, cutting-edge research. For example, a 1997 grant went to Wei Wen, PhD, and her sponsor Judah Folkman, MD, for further study of the angiogenesis inhibitor endostatin.

Each year, the Foundation’s National Research Fellowship Program offers postdoctoral fellowship grants for breast cancer research to qualified applicants with MD or PhD degrees.

The 3-year grant offers an experienced breast cancer investigator the opportunity to select a postdoctoral fellow to train in his or her laboratory. Grant recipients are selected through a peer-review process that is recognized by the National Cancer Institute. The annual stipend is $35,000 per award.

For more information about the grants program, contact Elda Railey, director of grants, via email at grants@komen.org or by calling 888-300-5582.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content